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Abstract
Background: The Wnt signaling pathway plays critical roles in cell proliferation and cell fate
determination at many stages of development. A critical downstream target of Wnt signaling is the
cytosolic β-catenin, which is stabilized upon Wnt activation and promotes transcription of a variety
of target genes including c-myc and cyclin D. Aberrant Wnt signaling, which results from mutations
of either β-catenin or adenomatous polyposis coli (APC), renders β-catenin resistant to
degradation, and has been associated with multiple types of human cancers.
Results: A protein knockdown strategy was designed to reduce the cytosolic β-catenin levels
through accelerating its turnover rate. By engineering a chimeric protein with the β-catenin binding
domain of E-cadherin fused to βTrCP ubiquitin-protein ligase, the stable β-catenin mutant was
recruited to the cellular SCF (Skp1, Cullin 1, and F-box-containing substrate receptor)
ubiquitination machinery for ubiquitination and degradation. The DLD1 colon cancer cells express
wild type β-catenin at abnormally high levels due to loss of APC. Remarkably, conditional
expression of βTrCP-E-cadherin under the control of a tetracycline-repressive promoter in DLD1
cells selectively knocked down the cytosolic, but not membrane-associated subpopulation of β-
catenin. As a result, DLD1 cells were impaired in their growth and clonogenic ability in vitro, and
lost their tumorigenic potential in nude mice.
Conclusion: We have designed a novel approach to induce degradation of stabilized/mutated β-
catenin. Our results suggest that a high concentration of cytoplasmic β-catenin is critical for the
growth of colorectal tumor cells. The protein knockdown strategy can be utilized not only as a
novel method to dissect the role of oncoproteins in tumorigenesis, but also as a unique tool to
delineate the function of a subpopulation of proteins localized to a specific subcellular
compartment.
Background
Wnt signaling plays diverse roles at many stages of devel-
opment by regulating the stability of β-catenin [1]. In cells
that do not receive a Wnt signal, cytoplasmic β-catenin is
bound to a multi-protein β-catenin destruction complex
that contains several proteins including Axin, APC, and
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glycogen synthase kinase-3 (GSK3), and it is constitutively
phosphorylated at a cluster of Ser and Thr residues at its
N-terminus by GSK3. Phosphorylated β-catenin is recog-
nized by βTrCP, a component of the SCFβTrCP ubiquitin-
protein ligase complex, and degraded by the ubiquitin-
proteasome pathway. Wnt signaling disassembles the β-
catenin destruction complex, which prevents the phos-
phorylation and subsequent ubiquitination of β-catenin,
thus diverting β-catenin from the proteasome machinery.
Accumulated β-catenin then enters the nucleus, binds to
the LEF/TCF family transcription factors, and activates the
expression of β-catenin target genes.
Deregulated Wnt signaling contributes to tumorigenesis.
Wnt-1, the founding member of the Wnt family, was first
identified as a gene activated by insertion of a mouse
mammary tumor provirus, leading to the formation of
mouse mammary tumors [2]. Aberrant activation of Wnt
signaling, which results from activating mutations of β-
catenin or inactivating mutations of APC or Axin, has
been associated with a wide variety of human malignan-
cies, such as colorectal, heptocellular, ovarian endome-
trial, desmoid, and pancreatic tumors [3]. Among these
tumor types, Wnt signaling is most frequently deregulated
in colorectal tumors. APC is mutated in the majority of
colorectal cancers, and those tumors with wild-type APC
often contain mutated β-catenin [4]. Thus, aberrant acti-
vation of Wnt signaling appears to be obligatory for the
initiation or progression of colorectal tumors. Recent
studies suggested that β-catenin promotes tumorigenesis
through increasing the expression of oncogenes like c-myc
and cyclin D1 [5–7].
β-catenin is a "dual function" protein, which is deter-
mined by its membrane and nuclear localizations. Mem-
brane-associated β-catenin plays an important role in cell-
cell adhesion. It binds to the intracellular domain of E-
cadherin, and links E-cadherin to α-catenin and thereby
to the cortical actin cytoskeleton. E-cadherin-mediated
cell adhesion plays an inhibitory role in tumor invasion
[8], and loss of E-cadherin promotes tumor progression
[9]. Nuclear β-catenin enhances transcription of Wnt-
responsive genes through interacting with TCF/LEF tran-
scription factors and recruiting different transcriptional
co-activators to the TCF/LEF binding sites.
To study the function of β-catenin in tumorigenesis, one
needs to develop a strategy to selectively block the nuclear
activity of β-catenin while leaving the membrane activity
of β-catenin intact. Such an approach would enhance our
understanding of the oncogenic function of β-catenin,
and might further serve as a strategy for targeted therapy
for tumors derived from aberrant Wnt signaling. In this
study, a protein knockdown method was designed to
induce the degradation of unphosphorylated β-catenin,
which resulted in the suppression of neoplastic growth of
colorectal tumor cells.
Results
Ubiquitin-dependent proteolysis constitutes the major
pathway for eukaryotic cells to degrade specific proteins.
This pathway involves a cascade of enzymatic reactions
catalyzed by the E1 ubiquitin-activating enzyme, the E2
ubiquitin-conjugating enzyme, and the E3 ubiquitin-pro-
tein ligase [10]. The substrate specificity of this system is
determined by the E3 ligase. One such E3 ligase, desig-
nated SCF (Skp1, Cul-1, F-box-containing substrate recep-
tor, and the Ring domain protein Rbx1/Roc1/Hrt1), is a
multimeric protein complex that targets key regulators of
cell cycle and signaling pathways for ubiquitination
(reviewed in [11]). Among the SCF subunits, the F box
proteins serve as receptors that recruit substrates through
various protein-protein interaction domains and bring
them to the core E3 (Skp1/Cul-1/Rbx1) through interac-
tion between the F box and Skp1. βTrCP is such an F box
protein that binds to its substrates, such as IκB and β-cat-
enin, through its WD40 repeats. Specifically, serine phos-
phorylation of IκB and β-catenin is a prerequisite for their
binding to βTrCP [12–15].
The SCF ubiquitination machinery can be harnessed to
degrade a specific target protein by fusing an F box protein
with a peptide that is able to bind to the target protein
[16]. Here we investigated whether an F-box protein can
be redesigned to target their usual substrates that have
become resistant to degradation (eg, by mutations in the
N-terminus of β-catenin). Recognition of β-catenin by
βTrCP normally requires phosphorylation of serine resi-
dues within the N-terminal DSGxxS motif of β-catein
[13,15]. To target unphosphorylated and thus stabilized
β-catenin to the core SCF for ubiquitination and degrada-
tion, we fused the β-catenin binding domain of E-cad-
herin (amino acids 794–883, designated Ecad) to the C-
terminus of βTrCP (Fig. 1A). A glycine-serine-rich
sequence was inserted between βTrCP and Ecad to relieve
the potential steric hindrance between these two protein
structures. Ser37 is one major GSK3 phosphorylation site
of β-catenin that is recognized by βTrCP [13]. Substitution
of Ser37 with Ala abrogates the association between β-cat-
enin and βTrCP. It has been shown that β-catenin S37A is
about 9-fold more stable than the wild-type β-catenin
[17]. The binding between β-catenin S37A and βTrCP-
Ecad was assayed in 293 cells using a co-immunoprecipi-
tation assay. HA-tagged β-catenin S37A and FLAG-tagged
βTrCP-Ecad were coexpressed in 293 cells. Total cell
lysates were immunoprecipitated with the anti-FLAG anti-
body, and immunoprecipitates were subjected to SDS
PAGE and immunoblotting with the anti-HA antibody. As
shown in Fig. 1B, β-catenin S37A strongly interacted with
F-TrCP-Ecad, but not F-TrCP, indicating that theBMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/10
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Engineering a βTrCP-E-cadherin chimera that targets oncogenic β-catenin for degradation Figure 1
Engineering a βTrCP-E-cadherin chimera that targets oncogenic β-catenin for degradation. A. Schematic diagrams of F-TrCP-
Ecad chimeras used in this study. The β-catenin binding domain (amino acids 794–883) of E-cadherin (Ecad) was fused to the C-
terminus of FLAG-tagged βTrCP to form F-TrCP-Ecad. The N-terminus of βTrCP (amino acid 1–297) was deleted from F-
TrCP-Ecad to make F-TrCP(∆N)-Ecad. The transmembrane (TM) region and the β-catenin binding domain in E-cadherin are 
indicated. The F box of βTrCP is hatched. The FLAG epitope fused at the N-termini of βTrCP, βTrCP-Ecad, or βTrCP(∆N)-
Ecad is indicated by a solid rectangle. B. F-TrCP-Ecad binds to β-catenin S37A in vivo. HA-tagged β-catenin S37A and FLAG-
tagged βTrCP derivatives were co-expressed in 293 cells. Cells were treated with the proteasome inhibitor MG132 for 4 
hours before harvesting. Cell lysates were immunoprecipitated with the anti-FLAG antibody, precipitates were resolved by a 
10% SDS-PAGE gel, transferred to a nitrocellulose membrane, and immunoblotted with the anti-HA antibody (top panel). 
Note that a nonspecific band that cross-reacted with the anti-HA antibody migrated slightly above β-catenin S37A in all lanes of 
this panel. The membrane was stripped and blotted with the anti-FLAG antibody (middle panel). The expression of β-catenin 
S37A in total cell lysates was examined by immunoblotting with the anti-HA antibody (bottom panel). C. F-TrCP-Ecad induces 
ubiquitination of β-catenin S37A in vivo. MYC-tagged β-catenin S37A, HA-tagged ubiquitin, and indicated βTrCP derivatives 
were co-expressed in 293 cells. Cells were treated with the proteasome inhibitor ALLN for 4 hours, and lysed in the denatur-
ing buffer by boiling to disrupt non-covalent protein-protein interactions. Cell lysates were immunoprecipitated with the anti-
HA antibody, and immunoprecipitates were resolved in SDS-PAGE and blotted with the anti-MYC antibody (top panel). The 
expression of β-catenin S37A in total cell lysates was determined by immunoblotting with the anti-MYC antibody (bottom 
panel). D. F-TrCP-Ecad reduces the steady state levels of β-catenin. HA-tagged β-catenin and CDK2 were co-expressed with 
indicated βTrCP derivatives in 293 cells. Total cell lysates were resolved by SDS-PAGE, and immunoblotted with the anti-HA 
antibody.
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intracellular domain of E-cadherin binds to the armadillo
repeats of β-catenin in a phosphorylation-independent
manner.
Next, we tested whether binding between F-TrCP-Ecad
and β-catenin S37A could induce ubiquitination of β-cat-
enin S37A. 293 cells were cotransfected with plasmids
encoding HA-tagged ubiquitin and MYC-tagged β-catenin
S37A. Cell lysates were immunoprecipitated with the anti-
HA antibody under conditions that denature proteins in
cell lysates, and probed with an anti-MYC monoclonal
antibody against MYC-tagged β-catenin. As seen in Fig.
1C, β-catenin S37A was ubiquitinated only in the pres-
ence of F-TrCP-Ecad, but not F-TrCP.
To examine whether ectopic expression of F-TrCP-Ecad
affects degradation of β-catenin S37A, plasmids encoding
F-TrCP-Ecad and HA-tagged β-catenin S37A were cotrans-
fected into 293 cells. A plasmid encoding HA-tagged
CDK2 was also included in the transfection as an internal
control. Consistent with the association between F-TrCP-
Ecad and β-catenin S37A, co-expression of F-TrCP-Ecad
significantly reduced the steady state level of β-catenin
S37A, but not that of the control CDK2 (Fig. 1D). There-
fore, the engineered F-TrCP-Ecad can recapture the "non-
degradable" β-catenin S37A, and promote its ubiquitina-
tion and degradation.
We further tested the effect of F-TrCP-Ecad on the tran-
scriptional activity of β-catenin. β-catenin S37A was tran-
siently expressed in 293 cells with TOP-FLASH, a
luciferase reporter that contains multiple copies of TCF
binding sites and serves as a readout for β-catenin signal-
ing activity [18]. As shown in Fig. 2A, co-expression of F-
TrCP-Ecad dramatically decreased the transcriptional
response to β-catenin S37A from the TOP-FLASH reporter.
Two other β-catenin targeting peptides, which constitute
the N-terminal domains of human TCF4 or Xenopus TCF3,
were also fused to βTrCP, and demonstrated similar
inhibitory effects on β-catenin signaling as F-TrCP-Ecad
(data not shown).
The F box is critical for the ubiquitin-protein ligase activity
of βTrCP. To investigate whether βTrCP-mediated β-cat-
enin degradation is required for the attenuation of β-cat-
enin signaling, an N-terminal region of βTrCP, including
the F box, was deleted from F-TrCP-Ecad to form F-
TrCP(∆N)-Ecad, and tested for its effect on the transcrip-
tional activity of β-catenin. Deletion of the N-terminal
region from βTrCP resulted in a complete loss of inhibi-
tion of β-catenin signaling (Figure 2A), although F-
TrCP(∆N)-Ecad and F-TrCP-Ecad bound to β-catenin to
the similar extent (Figure 2B). This finding suggests that
the inhibitory effect of F-TrCP-Ecad on β-catenin signaling
is dependent on targeted degradation of β-catenin by the
engineered F-TrCP-Ecad ubiquitin-protein ligase.
There are two subpopulations of β-catenin inside cells, the
nuclear/cytosolic pool and the membrane pool. Only the
nuclear/cytosolic pool of β-catenin is subjected to direct
regulation by Wnt signaling. The nuclear β-catenin binds
to TCF/LEF transcriptional factors and activates the
expression of Wnt target genes. The membrane β-catenin
bridges the interaction between α-catenin and E-cadherin,
and links the E-cadherin complex to the actin
cytoskeleton.
We tested the effect of F-TrCP-Ecad induction on the levels
of the membrane and cytosolic β-catenin in the DLD1
colon cancer cells. β-catenin signaling is deregulated in
DLD1 cells due to inactivation mutations of APC, result-
ing in the accumulation of unphosphorylated β-catenin
resistant to βTrCP-mediated proteolysis. A stable DLD1-F-
TrCP-Ecad cell line was constructed in which the engi-
neered F-TrCP-Ecad was expressed under the tetracycline-
repressible promoter [19]. The expression of F-TrCP-Ecad
was induced when DLD1-F-TrCP-Ecad cells were cultured
in the absence of doxycycline (Dox), a tetracycline ana-
logue (Fig. 3C). To test whether induction of F-TrCP-Ecad
affects the steady state levels of the membrane and
cytosolic β-catenin, DLD1-F-TrCP-Ecad cells were grown
in the presence or the absence of Dox, and fractionated
into the cytosolic pool (S100) and the membrane pool
(P100) by centrifugation. As seen in Fig. 3A, induction of
F-TrCP-Ecad expression reduced the steady state level of
cytosolic β-catenin, while it had no effect on the level of
the membrane-associated β-catenin. In contrast, Dox
treatment of the parental DLD1 cells had no effect on the
steady state level of cytosolic β-catenin (data not shown).
Therefore, F-TrCP-Ecad preferentially targets soluble
nuclear/cytosolic β-catenin for degradation, sparing the
membrane-associated fraction, which is tightly associated
with endogenous membrane E-cadherin.
The signaling activity of β-catenin was further assessed in
response to induced expression of F-TrCP-Ecad. DLD1-F-
TrCP-Ecad cells were transiently transfected with TOP-
FLASH and a control plasmid encoding Renilla luciferase,
then cultured in the presence or the absence of Dox. As
seen in Fig. 3B, induction of F-TrCP-Ecad reduced TOP-
FLASH activity by 4-fold, indicating decreased β-catenin
signaling activity.
c-myc has been previously identified as a β-catenin target
gene in colon cancer cells [5]. We asked whether c-myc
expression was affected by down-regulation of β-catenin
signaling. Indeed, induction of F-TrCP-Ecad by Dox with-
drawal decreased the concentration of c-myc oncoprotein
(Fig. 3C).BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/10
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F-TrCP-Ecad inhibits the transcriptional activity of β-catenin S37A Figure 2
F-TrCP-Ecad inhibits the transcriptional activity of β-catenin S37A. A. 293 cells were co-transfected with a β-catenin S37A 
expression plasmid, indicated βTrCP expression plasmids, TOP-FLASH, and a CMV-Renilla reporter. The luciferase activities 
were measured and normalized against the control Renilla activities (top panel). The luciferase activity of cells transfected with 
βTrCP was arbitrarily set to 1. The expression of βTrCP derivatives was determined by immunoblotting with the anti-FLAG 
antibody (bottom panel). B. F-TrCP-Ecad and F-TrCP(∆N)-Ecad bind to β-catenin to the similar extent. HA-tagged β-catenin 
S37A and FLAG-tagged βTrCP derivatives were co-expressed in 293 cells. Cells were treated with the proteasome inhibitor 
MG132 for 4 hours before harvesting. Cell lysates were immunoprecipitated with the anti-FLAG antibody, precipitates were 
resolved by SDS-PAGE and immunoblotted with the anti-HA antibody (top panel). The expression of FLAG-tagged βTrCP 
derivatives and β-catenin S37A in total cell lysates was examined by immunoblotting with the anti-FLAG and anti-HA antibod-
ies (middle and bottom panels).
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F-TrCP-Ecad promotes β-catenin degradation and inhibits Wnt signaling in DLD1 cells Figure 3
F-TrCP-Ecad promotes β-catenin degradation and inhibits Wnt signaling in DLD1 cells. A. Effects of F-TrCP-Ecad on the levels 
of cytosolic and membrane-associated β-catenin. A DLD1 inducible cell line was generated with the tetracycline (tet)-off sys-
tem; these cells expressed F-TrCP-Ecad only in the absence of Dox. Cells were grown in the presence or absence of Dox for 
5 days, and subjected to subcellular fractionation. Equal amounts of proteins were resolved by SDS-PAGE, transferred to nitro-
cellulose membranes, and blotted with the anti-β-catenin antibody. α-tubulin levels were determined by immunoblotting with 
the anti-α-tubulin antibody as an internal loading control. Quantified representation of immunoblot is shown at the bottom of 
each blot (relative intensity). B. F-TrCP-Ecad inhibits the transcriptional activity of β-catenin. DLD1-F-TrCP-Ecad cells were 
transfected with TOP-FLASH and a CMV-Renilla reporter, and cultured in the presence or absence of Dox. The luciferase 
activity of cells grown in the presence of Dox was arbitrarily set to 1. C. F-TrCP-Ecad induction inhibits c-MYC expression. 
DLD1-F-TrCP-Ecad cells were cultured in the presence or absence of Dox for four days. The expression level of c-myc and F-
TrCP-Ecad were determined by immunoblotting with the anti-MYC (C-19) and the anti-FLAG antibodies (top and middle pan-
els). Equal loadings were confirmed by immunoblotting with the anti-α-tubulin antibody (bottom panel). 'o' indicates two 
unknown species immuno-reactive with the anti-FLAG antibody, which migrated right below βTrCP-Ecad of the middle panel.
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To study the effect of F-TrCP-Ecad induction on cell pro-
liferation, we first measured the growth rate of DLD1-F-
TrCP-Ecad cells in the presence or absence of Dox. A
reduced rate of cell growth was observed when cells were
cultured in the absence of Dox (Fig. 4A). This effect of F-
TrCP-Ecad on cell proliferation was not a result of
increased cell death, as determined by trypan blue stain-
ing (data not shown). A clonogenic assay was performed,
in which DLD1-F-TrCP-Ecad cells were plated at a low
density (2,000 cells/10 cm plate) and cultured in the pres-
ence or absence of Dox. Induction of F-TrCP-Ecad expres-
sion dramatically reduced the colony forming capability
of DLD1 cells (Fig. 4B).
The effect of targeted-degradation of β-catenin on the
tumorigenicity of DLD1 cells was examined by subcutane-
ous injection of DLD1-F-TrCP-Ecad cells into nude mice.
Remarkably, nude mice fed with Dox-free food exhibited
significant attenuation of tumor growth compared with
those treated with Dox, indicating a requirement for
maintenance of β-catenin levels for the tumorigenicity of
DLD1 cells in vivo (Fig. 4C).
Collectively, these results provide strong evidence that
induced expression of the engineered F-TrCP-Ecad ubiqui-
tin-protein ligase downregulated β-catenin levels and sig-
nificantly blocked Wnt signaling in and tumorigenicity of
a colon cancer cell.
Discussion
The stability of β-catenin is tightly regulated in normal
cells: β-catenin is constitutively phosphorylated by GSK3,
which triggers its recognition and degradation by the SCF-
βTrCP ubiquitination machinery. In tumor cells with aber-
rant activation of the Wnt signaling pathway, β-catenin is
no longer phosphorylated due to mutations in β-catenin
itself or upstream elements that are critical for its phos-
phorylation, and thus escapes degradation. We have
designed a protein knockdown strategy to recapture non-
phosphorylated cytoplasmic β-catenin and to target it to
the SCF machinery for degradation. This knockdown
strategy can degrade both mutant β-catenin lacking N-ter-
minal phosphorylation sites and wild-type β-catenin sta-
bilized by APC mutations, and it preferentially targets
cytoplasmic versus membrane β-catenin. Finally, we show
that degradation of β-catenin results in inhibition of
colorectal tumor cell growth both in vitro and in vivo.
β-catenin has both membrane and nuclear functions. To
inhibit β-catenin signaling, one needs to specifically block
the nuclear function of β-catenin while leaving the mem-
brane function of β-catenin intact. Methods such as tar-
geted gene knockout mutagenesis, RNA interference, or
inhibition with antisense oligonucleotides will eliminate
both the nuclear and the membrane functions of β-cat-
enin. The nuclear function of β-catenin can be blocked by
enhancing the degradation of cytosolic β-catenin with
excess Axin [20,21] or APC [22,23]. However, neither
Axin nor APC can induce the degradation of β-catenin
mutants lacking N-terminal phosphorylation sites, and
Axin has an apoptotic activity that appears to be inde-
pendent of its effects on the Wnt pathway [24]. Another
way to block the nuclear function of β-catenin specifically
is to overexpress a dominant negative form of TCF; this
approach has proved to be valuable for studying the role
of the β-catenin in tumorigenesis [25]. However, there is
evidence that at least some signaling functions of β-cat-
enin might not be mediated by TCF. For example, activa-
tion of WISP-1 by Wnt and β-catenin appears to be TCF-
independent [26]. Recently, it has also been shown that
Pitx2 can recruit β-catenin to the promoter of Cyclin D2,
and activate the transcription of Cyclin D2 [27].
The F-TrCP-Ecad chimera that we have engineered
decreases the levels of cytosolic and presumably nuclear β-
catenin, but has no obvious effect on the levels of
membrane β-catenin. βTrCP has a short half-life [28](J.Z.
and P.Z., unpublished results), so the steady state level of
F-TrCP-Ecad in cells is likely low. It is possible that β-cat-
enin, when in complex with the membrane E-cadherin, is
protected from the action of F-TrCP-Ecad. However, pro-
longed high level expression of F-TrCP-Ecad eventually
affects the abundance of membrane β-catenin through
affecting the equilibrium between the two pools of β-cat-
enin (J.Z. and P.Z., unpublished results).
In this study, we have found that down-regulation of β-
catenin signaling in DLD1 cells reduces c-myc expression
levels and impairs cell growth (Fig. 3 and 4) without caus-
ing obvious cell death (data not shown). Similarly, van de
Wetering et al have shown that overexpression of a domi-
nant-negative form of TCF4 in colon cancer cells causes
growth arrest but not cell death [25]. Importantly, ectopic
expression of c-myc can reverse the growth arrest induced
by dominant-negative TCF4, demonstrating that c-myc is
a crucial mediator of β-catenin oncogenic activity [25].
We have shown that the tumorigenicity of DLD1 cells
appears to be dependent on the concentration of cytoplas-
mic β-catenin. However, this may not be true for all colon
cancer cells with stabilized β-catenin. Using somatic cell
gene targeting to disrupt either wild-type or mutant form
of β-catenin, it has been shown that elevated β-catenin is
not essential for the growth of HCT116 cells [29,30], but
is required for the growth of DLD1 and SW48 cells [30].
Presumably, additional mutations in HCT116 cells over-
ride the need for an oncogenic signal mediated by β-cat-
enin.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/10
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F-TrCP-Ecad inhibits clonogenic and tumorigenic potential of DLD1 cells Figure 4
F-TrCP-Ecad inhibits clonogenic and tumorigenic potential of DLD1 cells. A. βTrCP-Ecad inhibits the growth rate of DLD1 
cells. DLD1-F-TrCP-Ecad cells were grown in the presence or the absence of Dox for five days. The numbers of cells were 
counted daily in triplicates. B. Induction of F-TrCP-Ecad decreases the colony forming ability of DLD1 cells. DLD1-F-TrCP-
Ecad cells were diluted, plated at a low density, and cultured in the presence or the absence of Dox for 14 days. Plates were 
photographed (top panel) and the number of colonies was counted (bottom panel). The experiment was performed in tripli-
cates C. F-TrCP-Ecad induction inhibits tumorigenicity of DLD1 cells in nude mice. 2 × 106 DLD1-F-TrCP-Ecad cells were 
injected subcutaneously in nude mice. Each mouse received three injections. Nude mice were fed with either regular or Dox-
containing food, and photographed three weeks after injection. In this observation period, six of six injections gave rise to 
tumors (indicated with asterisks) on mice fed with Dox-impregnated food, while none of the six injections generated tumor on 
mice fed with regular food.
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Cancer stems from the step-wise accumulation of genetic
changes. In simplified mouse models for cancer, contin-
ued activity of an initiating oncogene is usually required
for tumor growth [31]. However, one cancer-causing gene
important for tumor initiation might also become dispen-
sable for tumor maintenance due to accumulation of
additional mutations when the tumor progresses to an
advanced stage [32]. Therefore, it is necessary to establish
whether an oncoprotein in a late stage tumor is still a valid
molecular target for the development of pharmacological
inhibitors. The protein knockdown system provides a
unique strategy for assessing the contribution of each
oncoprotein to the tumorigenic phenotype of a late stage
tumor as well as a novel approach for targeted tumor
therapy.
Conclusions
We have developed a protein knockdown strategy to
degrade unphosphorylated or mutated β-catenin, and
demonstrated that suppression of β-catenin inhibits the
neoplastic growth of colorectal tumor cells.
Methods
Cell culture
The 293 cell line was obtained from the American Type
Culture Collection and cultured in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine
serum (Hyclone), 100 units/ml of penicillin, and 100 µg/
ml of streptomycin. A tetracycline (tet)-off system was
used for inducible expression of F-TrCP-Ecad protein. In
this system, the repression of gene expression was
achieved by maintaining cells in the presence of a tetracy-
cline analog, doxycycline (Dox) and the induction of gene
expression was achieved by Dox withdrawal. The DLD1-
tTA cell line was a generous gift of Bert Vogelstein [19],
which expresses tetracycline-suppressible transactivator
(tTA)-IRES-neo under control of the CMV promoter. The
DLD1-tTA cells were maintained in McCoy's 5A, 10% fetal
bovine serum, 400 µg/ml G418, and 20 ng/ml Dox (ICN).
The F-TrCP-Ecad expression construct was generated by
cloning F-TrCP-Ecad into pBI-MCS-EGFP [19]. The con-
struct was linearized and cotransfected with pTK-hygro
(Clontech) into DLD1-tTA cells. Single colonies were
obtained by limiting dilution with medium containing
400 µg/ml G418, 250 µg/ml hygromycin B (Clontech),
and 20 ng/ml of Dox for three weeks. Clones with homog-
enous GFP induction were subjected to immunoblot anal-
ysis for the expression of F-TrCP-Ecad with anti-FLAG
antibodies (Sigma). 293 and DLD1 cells were transfected
with a calcium phosphate transfection kit (Stratagene).
Luciferase Reporter assay
Cells were split into 12-well plates 24 hours before trans-
fection. Each well received 0.2 µg TOP-FLASH, 0.02 µg
CMV-Renilla  expression plasmid, together with 0.5 µg
indicated plasmids. Thirty-six hour after transfection, cells
were lysed and luciferase assays were performed with the
Dual Luciferase Assay kit (Promega) according to the
manufacturer's instructions. The luciferase activity was
normalized with the Renilla activity.
Co-immunoprecipitation and immunoblotting assay
For co-immunoprecipitation experiments cells were lysed
in EBC buffer (50 mM Tris, PH 7.6, 120 mM NaCl, 0.5%
NP-40, 1 mM EDTA, 1 mM DTT, and protease inhibitors).
Cell lysates were clarified by centrifugation at 13,000 rpm
for 15 minutes at 4°C. For immunoprecipitation, the cell
lysates were incubated with 1 µg of appropriate antibodies
at 4°C for 1 to 2 hours. The immunocomplexes were col-
lected with Protein A or Protein G agarose beads, and
washed five times with lysis buffer. The bound proteins
were eluted with Laemmli sample buffer. Proteins were
separated by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to nitrocellulose mem-
branes. Membranes were blocked with 5% nonfat dry
milk for 1 hour at room temperature, and incubated with
appropriate primary antibodies for 1 hour. Membranes
were then washed and incubated with horseradish perox-
idase (HRP)-conjugated anti-mouse or anti-rabbit IgG
secondary antibodies for 1 hour. Membranes were washed
extensively with TBST and developed with an ECL kit
(Amersham). Protein bands were semiquantitated by
densitometry. Commercial antibodies used in this study
include anti-FLAG (M2) and anti-α-tubulin monoclonal
antibodies (Sigma), anti-HA (HA.11) monoclonal anti-
body (Covance), anti-β-catenin monoclonal antibody
(Transduction Laboratories), anti-MYC (9E10) mono-
clonal antibody and anti-MYC (C-19) polyclonal anti-
body (Santa Cruz).
Cell fractionation assay
DLD1-F-TrCP-Ecad cells were grown in medium with or
without Dox for 5 days before being harvested. Cells were
washed and scraped on ice into TBS (10 mM Tris-HCl, pH
7.5, 140 mM NaCl, 2 mM DTT, protease inhibitors). Cells
were homogenized with 30 strokes in a dounce homoge-
nizer, and the nuclei were removed by low speed centrifu-
gation. The post-nuclear supernatants were spun at
100,000 g for 90 min at 4°C to generate a supernatant, or
cytosolic, fraction and membrane-rich pellet fraction.
Samples normalized for protein content were analyzed by
SDS-PAGE.
Cell growth and colony formation assay
For growth curve analysis, cells (105) were seeded into a
well of 6-well plates in the presence or the absence of 20
ng/ml Dox. Each day of 5 days, cells were counted using a
hemocytometer after trypsinization. For colony formation
assay, cells were plated at 2,000 cells/10 cm plate. CellsBMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/10
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were grown in the presence or the absence of Dox for 14
days and stained with 0.05% crystal violet (Sigma).
In vivo Ubiquitination assay
293 cells were transfected with a HA-tagged ubiquitin
expression construct together with indicated plasmids.
Thirty-six hours after transfection, cells were treated with
the proteosomal inhibitor N-acetyl-leucinyl-leucinyl-nor-
leucinyl-H (ALLN) for four hours. Cells were then har-
vested and lysed in 1% SDS lysis buffer (50 mM Tris-HCl
pH7.5, 0.5 mM EDTA, 1% SDS, 1 mM DTT, protease
inhibitors). Cell lysates were sonicated, heated at 80°C for
30 minutes, and clarified by centrifugation. Supernatants
were diluted 10 times in Triton X-100 lysis buffer (50 mM
Tri-HCl pH8.0, 150 mM NaCl, 1% Triton X-100, protease
inhibitors). Cell lysates were incubated with anti-HA
affinity matrix (Roche) overnight at 4°C. Immunoprecip-
itates were washed with Triton X-100 lysis buffer 5 times.
The bound proteins were eluted with Laemmli sample
buffer. Proteins were separated by SDS-PAGE, transferred
to nitrocellulose membranes, and subjected to immunob-
lotting analysis.
Nude mouse assay
2 × 106 of DLD1-F-TrCP-Ecad cells were injected subcuta-
neously into 8-week-old athymic nu/nu (nude) mice
(NCI). Animals were administered with regular or Dox-
impregnated food pellets, and inspected for 3 weeks.
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